Compare UFPT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UFPT | PHVS |
|---|---|---|
| Founded | 1963 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1996 | 2020 |
| Metric | UFPT | PHVS |
|---|---|---|
| Price | $204.79 | $26.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $289.00 | $40.70 |
| AVG Volume (30 Days) | ★ 187.1K | 99.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.44 | N/A |
| EPS | ★ 8.75 | N/A |
| Revenue | ★ $602,797,000.00 | N/A |
| Revenue This Year | $8.33 | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $23.93 | ★ N/A |
| Revenue Growth | ★ 19.50 | N/A |
| 52 Week Low | $178.26 | $11.51 |
| 52 Week High | $274.93 | $29.80 |
| Indicator | UFPT | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 46.60 |
| Support Level | $188.43 | $24.05 |
| Resistance Level | $206.13 | $28.43 |
| Average True Range (ATR) | 12.35 | 1.16 |
| MACD | -0.82 | -0.14 |
| Stochastic Oscillator | 16.36 | 32.41 |
UFP Technologies Inc is a designer and custom manufacturer of components, subassemblies, products, and packaging utilizing specialized foams, films, and plastics for the medical market. The company manufactures its products by converting raw materials using laminating, molding, radio frequency and impulse welding, and fabricating manufacturing techniques. It is an important link in the medical device supply chain and a valued outsource partner to many of the top medical device manufacturers in the world. The company's single-use and single-patient devices and components are used in a wide range of medical devices, disposable wound care products, infection prevention, minimally invasive surgery, wearables, orthopedic soft goods, and orthopedic implant packaging.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.